HIV drug resistance report 2017 (sólo en inglés)

This second HIVDR report has been jointly developed by WHO, the United States Centers for Disease Control and Prevention (US-CDC) and the Global Fund to Fight AIDS, Tuberculosis and Malaria (“The Global Fund”). It provides an update on recent population levels of HIVDR covering the period 2014–2016. The report includes data from 16 nationally representative surveys from 14 countries1 estimating resistance in: adults initiating ART (PDR), children younger than 18 months newly diagnosed with HIV, and adults on ART (acquired HIV drug resistance or ADR). To contextualize results from representative HIVDR surveys, the report is supported by systematic reviews of the published literature on PDR in adults, children and adolescents, and ADR in paediatric and adult populations. Finally, the report includes the prevalence of transmitted HIV drug resistance (TDR) in recently infected people in Malawi and Zimbabwe, estimated as part of recent household Population-based HIV Impact Assessment (PHIA) surveys, supported by the United States President’s Emergency Plan for AIDS Relief (PEPFAR).